Cassava Sciences Responds to Allegations that Data is Manipulated and “Defies Logic”
Alzheimer’s drug developer Cassava Sciences found its stock down by 19% in pre-market trading Wednesday
Alzheimer’s drug developer Cassava Sciences found its stock down by 19% in pre-market trading Wednesday